Dr. Julen Oyarzabal
Dr. Julen Oyarzabal obtained his Ph.D. in Pharmaceutical and Organic Chemistry from University of Basque Country in 1998. After his Ph.D., he moved to the University of California San Francisco (CA); and later, he joined the University of Southampton (UK) where he worked in computational chemistry. In November 2001 he joined Johnson & Johnson Pharmaceutical R&D where he led several projects, from molecular design and chemoinformatics perspective, in the CNS therapeutic area. In October 2006, after leaving J&J, he joined the Spanish National Cancer Research Centre (CNIO) where he set up and led the Computational Medicinal Chemistry and Chemoinformatics Section. After 4 years, in September 2010 he left CNIO and joined the Center for Applied Medical Research (CIMA), at the University of Navarra, to set up the small molecule discovery platform and led the Molecular Therapeutics Program. With research interests in chemoinformatics and competitive intelligence tools, the group is running a comprehensive program, from drug discovery informatics to chemical biology and medicinal chemistry, focused on derisking drug discovery. To date, Dr. Oyarzabal has published more than 60 research papers (e.g. Angew Chem, J Med Chem, Nature Comm, Neuropsychopharma, … as PI or co-PI). He is also co-inventor of 24 published PCT patent applications. Dr. Oyarzabal is Director of Translational Sciences of the CIMA, on the Board of Directors for the Academic Drug Discovery Consortium (ADDC), and a member of the European Medicines Agency (EMA) experts panel.